Innate Pharma (IPHYF) Current Assets (2017 - 2025)

Innate Pharma's Current Assets history spans 9 years, with the latest figure at $54.4 million for Q4 2025.

  • For Q4 2025, Current Assets fell 40.66% year-over-year to $54.4 million; the TTM value through Dec 2025 reached $54.4 million, down 40.66%, while the annual FY2025 figure was $54.4 million, 41.41% down from the prior year.
  • Current Assets reached $54.4 million in Q4 2025 per IPHYF's latest filing, down from $91.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $159.3 million in Q4 2023 to a low of $54.4 million in Q4 2025.
  • Average Current Assets over 5 years is $121.2 million, with a median of $142.7 million recorded in 2022.
  • Peak YoY movement for Current Assets: increased 11.63% in 2023, then tumbled 42.47% in 2024.
  • A 5-year view of Current Assets shows it stood at $158.2 million in 2021, then decreased by 9.8% to $142.7 million in 2022, then grew by 11.63% to $159.3 million in 2023, then crashed by 42.47% to $91.6 million in 2024, then plummeted by 40.66% to $54.4 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Current Assets are $54.4 million (Q4 2025), $91.6 million (Q4 2024), and $159.3 million (Q4 2023).